Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in this age group. We describe the clinical presentation, diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuhlman, Justin J, Alhaj Moustafa, Muhamad, Jiang, Liuyan, Wang, Jing, Gupta, Vivek, Tun, Han W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015786/
https://www.ncbi.nlm.nih.gov/pubmed/35444484
http://dx.doi.org/10.2147/BLCTT.S360442
_version_ 1784688385641676800
author Kuhlman, Justin J
Alhaj Moustafa, Muhamad
Jiang, Liuyan
Wang, Jing
Gupta, Vivek
Tun, Han W
author_facet Kuhlman, Justin J
Alhaj Moustafa, Muhamad
Jiang, Liuyan
Wang, Jing
Gupta, Vivek
Tun, Han W
author_sort Kuhlman, Justin J
collection PubMed
description Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in this age group. We describe the clinical presentation, diagnostic workup, and treatment outcome in two 80-year-old patients diagnosed with PCNSL who were treated with ibrutinib therapy. Both patients remain in complete remission following treatment with ibrutinib therapy. One patient is currently 4 years and the other is 2 years and 9 months from the time of initial diagnosis. We suggest that ibrutinib therapy has significant therapeutic activity against PCNSL in the newly diagnosed setting and should be evaluated in a clinical trial as part of front-line therapy, especially in elderly patients.
format Online
Article
Text
id pubmed-9015786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90157862022-04-19 Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Kuhlman, Justin J Alhaj Moustafa, Muhamad Jiang, Liuyan Wang, Jing Gupta, Vivek Tun, Han W Blood Lymphat Cancer Case Series Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in this age group. We describe the clinical presentation, diagnostic workup, and treatment outcome in two 80-year-old patients diagnosed with PCNSL who were treated with ibrutinib therapy. Both patients remain in complete remission following treatment with ibrutinib therapy. One patient is currently 4 years and the other is 2 years and 9 months from the time of initial diagnosis. We suggest that ibrutinib therapy has significant therapeutic activity against PCNSL in the newly diagnosed setting and should be evaluated in a clinical trial as part of front-line therapy, especially in elderly patients. Dove 2022-04-14 /pmc/articles/PMC9015786/ /pubmed/35444484 http://dx.doi.org/10.2147/BLCTT.S360442 Text en © 2022 Kuhlman et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Kuhlman, Justin J
Alhaj Moustafa, Muhamad
Jiang, Liuyan
Wang, Jing
Gupta, Vivek
Tun, Han W
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title_full Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title_fullStr Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title_full_unstemmed Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title_short Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
title_sort long-term survival with ibrutinib therapy in elderly patients with newly diagnosed primary central nervous system lymphoma
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015786/
https://www.ncbi.nlm.nih.gov/pubmed/35444484
http://dx.doi.org/10.2147/BLCTT.S360442
work_keys_str_mv AT kuhlmanjustinj longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma
AT alhajmoustafamuhamad longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma
AT jiangliuyan longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma
AT wangjing longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma
AT guptavivek longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma
AT tunhanw longtermsurvivalwithibrutinibtherapyinelderlypatientswithnewlydiagnosedprimarycentralnervoussystemlymphoma

Ejemplares similares